RifAXIMin (Systemic)
Brand names: Xifaxan
Drug class:
Antineoplastic Agents
Usage of RifAXIMin (Systemic)
Hepatic Encephalopathy
Reduction of risk of recurrence of overt hepatic encephalopathy in adults.
Guidelines generally recommend rifaximin as an adjunct to lactulose for prevention of hepatic encephalopathy recurrence in patients who have had at least 1 episode of overt hepatic encephalopathy while receiving lactulose alone.
Has been used in the treatment of hepatic encephalopathy† [off-label] to reduce blood ammonia concentrations and decrease severity of neurologic manifestations; designated an orphan drug by FDA for treatment of this condition.
Information from the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) regarding the management of hepatic encephalopathy, including recommendations for treatment and prevention of recurrence, is available at [Web]. Treatment of overt hepatic encephalopathy first includes lactulose, while rifaximin is recommended as add-on therapy to prevent recurrence.
Irritable Bowel Syndrome with Diarrhea
Treatment of irritable bowel syndrome (IBS) with diarrhea in adults. Guidelines for diarrhea-predominant IBS generally include use of rifaximin for treating global symptoms. Rifaximin is also recommended for retreatment in those who had a response to rifaximin and develop recurrent symptoms.
Travelers’ Diarrhea
Treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli in adults and adolescents ≥12 years of age.
Not effective in and should not be used for treatment of diarrhea complicated by fever or bloody stools.
Not effective in and should not be used for treatment of diarrhea known or suspected to be caused by pathogens other than E. coli (e.g., Campylobacter jejuni, Shigella, Salmonella).
Travelers' diarrhea caused by bacteria may be self-limited and often resolves within 3–7 days without anti-infective treatment. Guidelines generally consider rifaximin an alternative to fluoroquinolones or azithromycin for noninvasive moderate-to-severe travelers’ diarrhea.
Has been used for prevention of travelers’ diarrhea† [off-label]. CDC and others state that anti-infective prophylaxis for prevention of travelers' diarrhea is not recommended for most travelers.
Other Uses
Has been used in some adults as treatment for the prevention of recurrence following standard treatment for Clostridioides difficile infection (CDI) in patients with multiple recurrences† [off-label].
Has been used in combination therapy for patients with refractory acute pouchitis,† [off-label] although safety and efficacy have not been established.
Has been used for treatment of small intestinal bacterial overgrowth,† [off-label] although safety and efficacy have not been established.
Relate drugs
- Abemaciclib (Systemic)
- Acyclovir (Systemic)
- Adenovirus Vaccine
- Aldomet
- Aluminum Acetate
- Aluminum Chloride (Topical)
- Ambien
- Ambien CR
- Aminosalicylic Acid
- Anacaulase
- Anacaulase
- Anifrolumab (Systemic)
- Antacids
- Anthrax Immune Globulin IV (Human)
- Antihemophilic Factor (Recombinant), Fc fusion protein (Systemic)
- Antihemophilic Factor (recombinant), Fc-VWF-XTEN Fusion Protein
- Antihemophilic Factor (recombinant), PEGylated
- Antithrombin alfa
- Antithrombin alfa
- Antithrombin III
- Antithrombin III
- Antithymocyte Globulin (Equine)
- Antivenin (Latrodectus mactans) (Equine)
- Apremilast (Systemic)
- Aprepitant/Fosaprepitant
- Articaine
- Asenapine
- Atracurium
- Atropine (EENT)
- Avacincaptad Pegol (EENT)
- Avacincaptad Pegol (EENT)
- Axicabtagene (Systemic)
- Clidinium
- Clindamycin (Systemic)
- Clonidine
- Clonidine (Epidural)
- Clonidine (Oral)
- Clonidine injection
- Clonidine transdermal
- Co-trimoxazole
- COVID-19 Vaccine (Janssen) (Systemic)
- COVID-19 Vaccine (Moderna)
- COVID-19 Vaccine (Pfizer-BioNTech)
- Crizanlizumab-tmca (Systemic)
- Cromolyn (EENT)
- Cromolyn (Systemic, Oral Inhalation)
- Crotalidae Polyvalent Immune Fab
- CycloSPORINE (EENT)
- CycloSPORINE (EENT)
- CycloSPORINE (Systemic)
- Cysteamine Bitartrate
- Cysteamine Hydrochloride
- Cysteamine Hydrochloride
- Cytomegalovirus Immune Globulin IV
- A1-Proteinase Inhibitor
- A1-Proteinase Inhibitor
- Bacitracin (EENT)
- Baloxavir
- Baloxavir
- Bazedoxifene
- Beclomethasone (EENT)
- Beclomethasone (Systemic, Oral Inhalation)
- Belladonna
- Belsomra
- Benralizumab (Systemic)
- Benzocaine (EENT)
- Bepotastine
- Betamethasone (Systemic)
- Betaxolol (EENT)
- Betaxolol (Systemic)
- Bexarotene (Systemic)
- Bismuth Salts
- Botulism Antitoxin (Equine)
- Brimonidine (EENT)
- Brivaracetam
- Brivaracetam
- Brolucizumab
- Brompheniramine
- Budesonide (EENT)
- Budesonide (Systemic, Oral Inhalation)
- Bulk-Forming Laxatives
- Bupivacaine (Local)
- BuPROPion (Systemic)
- Buspar
- Buspar Dividose
- Buspirone
- Butoconazole
- Cabotegravir (Systemic)
- Caffeine/Caffeine and Sodium Benzoate
- Calcitonin
- Calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate
- Calcium Salts
- Calcium, magnesium, potassium, and sodium oxybates
- Candida Albicans Skin Test Antigen
- Cantharidin (Topical)
- Capmatinib (Systemic)
- Carbachol
- Carbamide Peroxide
- Carbamide Peroxide
- Carmustine
- Castor Oil
- Catapres
- Catapres-TTS
- Catapres-TTS-1
- Catapres-TTS-2
- Catapres-TTS-3
- Ceftolozane/Tazobactam (Systemic)
- Cefuroxime
- Centruroides Immune F(ab′)2
- Cetirizine (EENT)
- Charcoal, Activated
- Chloramphenicol
- Chlorhexidine (EENT)
- Chlorhexidine (EENT)
- Cholera Vaccine Live Oral
- Choriogonadotropin Alfa
- Ciclesonide (EENT)
- Ciclesonide (Systemic, Oral Inhalation)
- Ciprofloxacin (EENT)
- Citrates
- Dacomitinib (Systemic)
- Dapsone (Systemic)
- Dapsone (Systemic)
- Daridorexant
- Darolutamide (Systemic)
- Dasatinib (Systemic)
- DAUNOrubicin and Cytarabine
- Dayvigo
- Dehydrated Alcohol
- Delafloxacin
- Delandistrogene Moxeparvovec (Systemic)
- Dengue Vaccine Live
- Dexamethasone (EENT)
- Dexamethasone (Systemic)
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine (Intravenous)
- Dexmedetomidine (Oromucosal)
- Dexmedetomidine buccal/sublingual
- Dexmedetomidine injection
- Dextran 40
- Diclofenac (Systemic)
- Dihydroergotamine
- Dimethyl Fumarate (Systemic)
- Diphenoxylate
- Diphtheria and Tetanus Toxoids
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- Diroximel Fumarate (Systemic)
- Docusate Salts
- Donislecel-jujn (Systemic)
- Doravirine, Lamivudine, and Tenofovir Disoproxil
- Doxepin (Systemic)
- Doxercalciferol
- Doxycycline (EENT)
- Doxycycline (Systemic)
- Doxycycline (Systemic)
- Doxylamine
- Duraclon
- Duraclon injection
- Dyclonine
- Edaravone
- Edluar
- Efgartigimod Alfa (Systemic)
- Eflornithine
- Eflornithine
- Elexacaftor, Tezacaftor, And Ivacaftor
- Elranatamab (Systemic)
- Elvitegravir, Cobicistat, Emtricitabine, and tenofovir Disoproxil Fumarate
- Emicizumab-kxwh (Systemic)
- Emtricitabine and Tenofovir Disoproxil Fumarate
- Entrectinib (Systemic)
- EPINEPHrine (EENT)
- EPINEPHrine (Systemic)
- Erythromycin (EENT)
- Erythromycin (Systemic)
- Estrogen-Progestin Combinations
- Estrogen-Progestin Combinations
- Estrogens, Conjugated
- Estropipate; Estrogens, Esterified
- Eszopiclone
- Ethchlorvynol
- Etranacogene Dezaparvovec
- Evinacumab (Systemic)
- Evinacumab (Systemic)
- Factor IX (Human), Factor IX Complex (Human)
- Factor IX (Recombinant)
- Factor IX (Recombinant), albumin fusion protein
- Factor IX (Recombinant), Fc fusion protein
- Factor VIIa (Recombinant)
- Factor Xa (recombinant), Inactivated-zhzo
- Factor Xa (recombinant), Inactivated-zhzo
- Factor XIII A-Subunit (Recombinant)
- Faricimab
- Fecal microbiota, live
- Fedratinib (Systemic)
- Fenofibric Acid/Fenofibrate
- Fibrinogen (Human)
- Flunisolide (EENT)
- Fluocinolone (EENT)
- Fluorides
- Fluorouracil (Systemic)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Fluticasone (EENT)
- Fluticasone (Systemic, Oral Inhalation)
- Fluticasone and Vilanterol (Oral Inhalation)
- Ganciclovir Sodium
- Gatifloxacin (EENT)
- Gentamicin (EENT)
- Gentamicin (Systemic)
- Gilteritinib (Systemic)
- Glofitamab
- Glycopyrronium
- Glycopyrronium
- Gonadotropin, Chorionic
- Goserelin
- Guanabenz
- Guanadrel
- Guanethidine
- Guanfacine
- Haemophilus b Vaccine
- Hepatitis A Virus Vaccine Inactivated
- Hepatitis B Vaccine Recombinant
- Hetlioz
- Hetlioz LQ
- Homatropine
- Hydrocortisone (EENT)
- Hydrocortisone (Systemic)
- Hydroquinone
- Hylorel
- Hyperosmotic Laxatives
- Ibandronate
- Igalmi buccal/sublingual
- Imipenem, Cilastatin Sodium, and Relebactam
- Inclisiran (Systemic)
- Infliximab, Infliximab-dyyb
- Influenza Vaccine Live Intranasal
- Influenza Vaccine Recombinant
- Influenza Virus Vaccine Inactivated
- Inotuzumab
- Insulin Human
- Interferon Alfa
- Interferon Beta
- Interferon Gamma
- Intermezzo
- Intuniv
- Iodoquinol (Topical)
- Iodoquinol (Topical)
- Ipratropium (EENT)
- Ipratropium (EENT)
- Ipratropium (Systemic, Oral Inhalation)
- Ismelin
- Isoproterenol
- Ivermectin (Systemic)
- Ivermectin (Topical)
- Ixazomib Citrate (Systemic)
- Japanese Encephalitis Vaccine
- Kapvay
- Ketoconazole (Systemic)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (Systemic)
- Ketotifen
- Lanthanum
- Lecanemab
- Lefamulin
- Lemborexant
- Lenacapavir (Systemic)
- Leniolisib
- Letermovir
- Letermovir
- Levodopa/Carbidopa
- LevoFLOXacin (EENT)
- LevoFLOXacin (Systemic)
- L-Glutamine
- Lidocaine (Local)
- Lidocaine (Systemic)
- Linezolid
- Lofexidine
- Loncastuximab
- Lotilaner (EENT)
- Lotilaner (EENT)
- Lucemyra
- Lumasiran Sodium
- Lumryz
- Lunesta
- Mannitol
- Mannitol
- Mb-Tab
- Measles, Mumps, and Rubella Vaccine
- Mecamylamine
- Mechlorethamine
- Mechlorethamine
- Melphalan (Systemic)
- Meningococcal Groups A, C, Y, and W-135 Vaccine
- Meprobamate
- Methoxy Polyethylene Glycol-epoetin Beta (Systemic)
- Methyldopa
- Methylergonovine, Ergonovine
- MetroNIDAZOLE (Systemic)
- MetroNIDAZOLE (Systemic)
- Miltown
- Minipress
- Minocycline (EENT)
- Minocycline (Systemic)
- Minoxidil (Systemic)
- Mometasone
- Mometasone (EENT)
- Moxifloxacin (EENT)
- Moxifloxacin (Systemic)
- Nalmefene
- Naloxone (Systemic)
- Natrol Melatonin + 5-HTP
- Nebivolol Hydrochloride
- Neomycin (EENT)
- Neomycin (Systemic)
- Netarsudil Mesylate
- Nexiclon XR
- Nicotine
- Nicotine
- Nicotine
- Nilotinib (Systemic)
- Nirmatrelvir
- Nirmatrelvir
- Nitroglycerin (Systemic)
- Ofloxacin (EENT)
- Ofloxacin (Systemic)
- Oliceridine Fumarate
- Olipudase Alfa-rpcp (Systemic)
- Olopatadine
- Omadacycline (Systemic)
- Osimertinib (Systemic)
- Oxacillin
- Oxymetazoline
- Pacritinib (Systemic)
- Palovarotene (Systemic)
- Paraldehyde
- Peginterferon Alfa
- Peginterferon Beta-1a (Systemic)
- Penicillin G
- Pentobarbital
- Pentosan
- Pilocarpine Hydrochloride
- Pilocarpine, Pilocarpine Hydrochloride, Pilocarpine Nitrate
- Placidyl
- Plasma Protein Fraction
- Plasminogen, Human-tmvh
- Pneumococcal Vaccine
- Polymyxin B (EENT)
- Polymyxin B (Systemic, Topical)
- PONATinib (Systemic)
- Poractant Alfa
- Posaconazole
- Potassium Supplements
- Pozelimab (Systemic)
- Pramoxine
- Prazosin
- Precedex
- Precedex injection
- PrednisoLONE (EENT)
- PrednisoLONE (Systemic)
- Progestins
- Propylhexedrine
- Protamine
- Protein C Concentrate
- Protein C Concentrate
- Prothrombin Complex Concentrate
- Pyrethrins with Piperonyl Butoxide
- Quviviq
- Ramelteon
- Relugolix, Estradiol, and Norethindrone Acetate
- Remdesivir (Systemic)
- Respiratory Syncytial Virus Vaccine, Adjuvanted (Systemic)
- RifAXIMin (Systemic)
- Roflumilast (Systemic)
- Roflumilast (Topical)
- Roflumilast (Topical)
- Rotavirus Vaccine Live Oral
- Rozanolixizumab (Systemic)
- Rozerem
- Ruxolitinib (Systemic)
- Saline Laxatives
- Selenious Acid
- Selexipag
- Selexipag
- Selpercatinib (Systemic)
- Sirolimus (Systemic)
- Sirolimus, albumin-bound
- Smallpox and Mpox Vaccine Live
- Smallpox Vaccine Live
- Sodium Chloride
- Sodium Ferric Gluconate
- Sodium Nitrite
- Sodium oxybate
- Sodium Phenylacetate and Sodium Benzoate
- Sodium Thiosulfate (Antidote) (Systemic)
- Sodium Thiosulfate (Protectant) (Systemic)
- Somatrogon (Systemic)
- Sonata
- Sotorasib (Systemic)
- Suvorexant
- Tacrolimus (Systemic)
- Tafenoquine (Arakoda)
- Tafenoquine (Krintafel)
- Talquetamab (Systemic)
- Tasimelteon
- Tedizolid
- Telotristat
- Tenex
- Terbinafine (Systemic)
- Tetrahydrozoline
- Tezacaftor and Ivacaftor
- Theophyllines
- Thrombin
- Thrombin Alfa (Recombinant) (Topical)
- Timolol (EENT)
- Timolol (Systemic)
- Tixagevimab and Cilgavimab
- Tobramycin (EENT)
- Tobramycin (Systemic)
- TraMADol (Systemic)
- Trametinib Dimethyl Sulfoxide
- Trancot
- Tremelimumab
- Tretinoin (Systemic)
- Triamcinolone (EENT)
- Triamcinolone (Systemic)
- Trimethobenzamide
- Tucatinib (Systemic)
- Unisom
- Vaccinia Immune Globulin IV
- Valoctocogene Roxaparvovec
- Valproate/Divalproex
- Valproate/Divalproex
- Vanspar
- Varenicline (Systemic)
- Varenicline (Systemic)
- Varenicline Tartrate (EENT)
- Vecamyl
- Vitamin B12
- Vonoprazan, Clarithromycin, and Amoxicillin
- Wytensin
- Xyrem
- Xywav
- Zaleplon
- Zirconium Cyclosilicate
- Zolpidem
- Zolpidem (Oral)
- Zolpidem (Oromucosal, Sublingual)
- ZolpiMist
- Zoster Vaccine Recombinant
- 5-hydroxytryptophan, melatonin, and pyridoxine
How to use RifAXIMin (Systemic)
General
Patient Monitoring
Administration
Oral Administration
Administer orally without regard to meals.
Dosage
Pediatric Patients
Travelers’ Diarrhea Treatment OralAdolescents ≥12 years of age: 200 mg three times daily for 3 days.
If diarrhea worsens or persists >24–48 hours after drug initiated, discontinue and consider alternative anti-infective.
Adults
Hepatic Encephalopathy Reduction of Risk of Recurrence of Overt Hepatic Encephalopathy Oral550 mg twice daily.
Treatment of Hepatic Encephalopathy† Oral600–1200 mg daily (usually in 3 divided doses) for 7–21 days.
Irritable Bowel Syndrome with Diarrhea Oral550 mg three times daily for 14 days.
If symptoms recur, up to 2 additional courses may be given using the same 14-day regimen.
Travelers’ Diarrhea Treatment Oral200 mg three times daily for 3 days.
If diarrhea worsens or persists >24–48 hours after drug initiated, discontinue and consider alternative anti-infective.
Prevention† Oral200–1100 mg daily, divided into 1–3 doses.
Clostridioides difficile Infection - Patients With Multiple Recurrences† Oral400 mg three times daily for 20 days or 400 mg three times daily for 14 days, followed by 200 mg three times daily for an additional 14 days.
Refractory Acute Pouchitis† Oral400 mg three times daily for 4 weeks or 1 gram twice daily for 15 days.
Small Intestinal Bacterial Overgrowth† Oral400 mg three times daily for 10 days.
Special Populations
Hepatic Impairment
Dosage adjustment not needed; use with caution in those with severe hepatic impairment (Child-Pugh class C).
Renal Impairment
No specific dosage recommendations at this time.
Geriatric Use
No specific dosage recommendations at this time.
Warnings
Contraindications
Warnings/Precautions
Travelers’ Diarrhea Not Caused by Escherichia Coli
Do not use for treatment of diarrhea complicated by fever or bloody stools.
Do not use for treatment of travelers’ diarrhea known or suspected to be caused by C. jejuni, Shigella, or Salmonella. Rifaximin was not effective for diarrhea due to pathogens other than E. coli.
If diarrhea worsens or persists >24–48 hours after initiating rifaximin, discontinue and consider use of another anti-infective.
Clostridium difficile-associated Diarrhea (CDAD)
Treatment with anti-infectives alters normal colon flora and may permit overgrowth of Clostridium difficile. CDI and CDAD (also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis) are reported with nearly all anti-infectives, including rifaximin, and may range in severity from mild diarrhea to fatal colitis. C. difficile produces toxins A and B, which contribute to development of CDAD; hypertoxin-producing strains of C. difficile are associated with increased morbidity and mortality since they may be refractory to anti-infectives and colectomy may be required.
Consider CDAD if diarrhea develops during or after therapy and manage accordingly. Obtain careful medical history since CDAD may occur as late as ≥2 months after anti-infective therapy is discontinued.
If CDAD suspected or confirmed, discontinue anti-infectives not directed against C. difficile whenever possible. Initiate appropriate supportive therapy, anti-infective therapy directed against C. difficile, and surgical evaluation as clinically indicated.
Development of Drug-Resistant Bacteria
Use for travelers’ diarrhea in absence of bacterial infection or a prophylactic indication is unlikely to provide benefit and increases risk of drug-resistant bacteria.
Severe (Child-Pugh Class C) Hepatic Impairment
Systemic exposure increased in severe hepatic impairment. Exercise caution when administering rifaximin to patients with severe hepatic impairment (Child-Pugh Class C).
Concomitant Use With P-glycoprotein Inhibitors
Concomitant use with P-glycoprotein (P-gp) transport inhibitors (e.g., cyclosporine) may substantially increase rifaximin systemic exposure. In patients with hepatic impairment, a potential additive effect of reduced hepatic metabolism and concomitant use with P-gp inhibitors may further increase rifaximin exposure. Exercise caution.
Specific Populations
PregnancyData not available regarding use in pregnant women. Teratogenic effects (e.g., ocular, oral and maxillofacial, cardiac, and lumbar spine malformations) observed in animal reproduction studies in rats and rabbits.
LactationNot known whether distributed into human milk; effects on human milk production or effects on breast-fed infant are not known.
Consider benefits of breast-feeding and importance of rifaximin to the female; also consider potential adverse effects on the breast-fed child from the drug or from the underlying maternal condition.
Pediatric UseHepatic encephalopathy: Safety and efficacy not established in children and adolescents <18 years of age.
IBS with diarrhea: Safety and efficacy not established in children and adolescents <18 years of age.
Travelers' diarrhea: Safety and efficacy not established in children <12 years of age.
Geriatric UseHepatic encephalopathy: No overall differences in safety or effectiveness observed between patients ≥65 years of age and younger adults.
IBS with diarrhea: No overall differences in safety or effectiveness observed between patients ≥65 years of age and younger adults.
Travelers' diarrhea: Experience in those ≥65 years of age insufficient to determine whether they respond differently than younger patients.
Hepatic ImpairmentAlthough dosage adjustments are not needed in patients with hepatic impairment, severe hepatic impairment (Child-Pugh class C) results in increased rifaximin systemic exposure and additional awareness and monitoring for rifaximin-related adverse effects would be suggested.
Hepatic encephalopathy: Clinical trials did not include patients with MELD scores >25.
Renal ImpairmentNot specifically studied in renal impairment.
Common Adverse Effects
Hepatic encephalopathy: Adverse effects (≥10%): peripheral edema, nausea, dizziness, fatigue, ascites.
IBS with diarrhea: Adverse effects (≥2%): nausea, increased ALT concentration.
Travelers' diarrhea: Adverse effects (≥2%): headache.
What other drugs will affect RifAXIMin (Systemic)
Substrate of CYP3A4. Does not inhibit CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, or 3A4 in vitro. Has induced CYP3A4 in vitro, but clinically important effects on intestinal or hepatic CYP3A4 unlikely.
Substrate of P-gp transport in vitro. Inhibits P-gp in vitro, but effect in vivo is unknown.
Substrate of organic anion transport polypeptides (OATP) 1A2, 1B1, and 1B3, but in vivo effect is unknown. Not a substrate of OATP2B1. Inhibits OATP1B1, 1A2, and 1B3 in vitro, but effect in vivo is unknown.
Drugs Affected by Hepatic Microsomal Enzymes
CYP3A4 substrates: Pharmacokinetic interactions not expected in patients with normal hepatic function; not known whether interactions occur in those with hepatic impairment resulting in increased rifaximin systemic exposure.
CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6, and 2E1 substrates: Pharmacokinetic interactions not expected.
Drugs Affecting or Affected by Transport Systems
P-gp inhibitors: Substantially increased rifaximin exposures may occur. Exercise caution with concomitant use; impaired hepatic function may further increase exposure to rifaximin.
P-gp substrates: Possible effects in vivo are unknown.
Specific Drugs
Drug
Interaction
Comments
Cyclosporine
Substantially increased rifaximin concentrations and AUC
Impaired hepatic function may result in additive exposure to rifaximin
Clinical importance unknown; exercise caution
Hormonal contraceptives (ethinyl estradiol and norgestimate)
Decreased ethinyl estradiol and norgestimate concentrations
Clinical importance unknown
Midazolam
No substantial changes in pharmacokinetics of midazolam or its major metabolite (1′-hydroxymidazolam)
Degree of interaction not clinically important
Warfarin
Changes in INR
Monitor PT and INR; dosage adjustments of warfarin may be necessary
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions